ResMed delivered solid first-quarter results with net revenue rising 5.9 percent to $1.41 billion and net income jumping 20 percent to $418.4 million, reflecting strong operational execution. Diluted earnings per share increased 23.2 percent to $2.92. The core Sleep and Breathing Health segment remains the primary growth driver, with revenue up 7.7 percent to $1.26 billion, though this is partially offset by weakness in Residential Care Software, which declined 6.6 percent to $155 million.
The Residential Care Software segment presents a point of concern for investors tracking the company’s diversification strategy. While the Sleep and Breathing Health business generated segment operating profit of $559.5 million, the software segment contributed $107.6 million despite lower revenue. This divergence in segment profitability suggests operational challenges in the software business that management will need to address. The declining revenue in this segment may reflect market headwinds, competitive pressure, or customer transition activity that warrant closer monitoring in upcoming quarters.
Operating expenses increased 12.5 percent to $417.6 million, outpacing revenue growth slightly, though gross profit grew faster at 6.4 percent to $870.6 million. The company’s gross margin remained relatively stable, indicating the expense increase reflects investments in research and development and selling, general and administrative functions. These investments support the company’s strategic direction while maintaining overall operating leverage on the enlarged revenue base.
ResMed initiated an aggressive capital return program during the quarter, entering into a $450 million accelerated share repurchase agreement and increasing its quarterly dividend by 10 percent to $0.66 per share from the prior year’s $0.60. The initial share repurchase settlement delivered 1.6 million shares representing approximately 80 percent of the total commitment. These actions reduced cash balances to $1.01 billion from $1.47 billion at the prior quarter-end, though the company maintains $1.5 billion in available borrowing capacity and has outstanding debt of approximately $410 million.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARInvestors should monitor the completion of the accelerated share repurchase, expected by late December 2026, and track whether management maintains the elevated dividend level going forward. The stabilization of Residential Care Software revenue will be critical to demonstrate that segment softness is temporary or manageable. The progression of operating margins and the company’s approach to future capital allocation will signal management’s confidence in the business trajectory. This announcement is price sensitive and has been classified as material by the ASX.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR